8-K: Labcorp Q3 2025 Results: Strong Growth, Raised EPS Outlook

Labcorp reported strong third-quarter 2025 financial results with significant revenue and adjusted EPS growth, alongside strategic acquisitions and an upward revision to its full-year adjusted EPS and free cash flow guidance.

Summary

• Labcorp announced third-quarter 2025 revenue of $3.56 billion, an 8.6% increase compared to $3.28 billion in Q3 2024.
• Diluted EPS for Q3 2025 was $3.12, up from $2.00 in Q3 2024.
• Adjusted EPS for Q3 2025 reached $4.18, a 19.4% increase from $3.50 in Q3 2024.
• Operating income grew to $396.6 million (11.1% of revenue) in Q3 2025 from $254.1 million (7.7% of revenue) in Q3 2024.
• Adjusted operating income was $513.3 million (14.4% of revenue) in Q3 2025, compared to $441.1 million (13.4% of revenue) in Q3 2024.
• Free cash flow for Q3 2025 was $280.5 million, significantly up from $161.5 million in Q3 2024.
• Full-year 2025 revenue guidance was updated to 7.4% to 8.0% growth, with the midpoint lowered by 40 basis points due to currency and acquisition timing.
• Full-year 2025 adjusted EPS guidance was raised to a range of $16.15 to $16.50, with the midpoint increasing by $0.05.
• Full-year 2025 free cash flow guidance was raised to a range of $1.17 billion to $1.29 billion, with the midpoint increasing by $25 million.
• Strategic agreements were signed to acquire select assets of Empire City Laboratories and Laboratory Alliance of Central New York, and to manage inpatient labs for Crouse Health.
• The acquisition of select oncology and clinical testing assets from BioReference Health was completed, strengthening Labcorp's oncology leadership.
• The company expanded its oncology and genetic testing portfolio, including OmniSeq INSIGHT for ovarian tumors, CE-marking for PGDx elio tissue complete, and FDA approval for Geneoscopy's ColoSense at-home collection.
• New Alzheimer's tests were introduced, and the consumer business saw momentum with new Labcorp OnDemand tests.
• Investments in digital and AI capabilities, including Labcorp Test Finder, were made to enhance customer experience and operational efficiency.

Sentiment

Score: 8

Explanation: The company reported strong financial results for Q3 2025, with significant growth in revenue, adjusted EPS, and free cash flow. Management raised full-year adjusted EPS and free cash flow guidance, indicating confidence. Strategic acquisitions and advancements in high-growth specialty testing areas further bolster the positive outlook, outweighing minor adjustments to revenue guidance and restructuring in a smaller segment.

Positives

• Third-quarter 2025 revenue increased by 8.6% to $3.56 billion, demonstrating strong top-line growth.
• Adjusted EPS grew by 19.4% to $4.18 in Q3 2025, reflecting improved profitability.
• Adjusted operating income margin expanded by 100 basis points to 14.4% in Q3 2025.
• Free cash flow significantly increased to $280.5 million in Q3 2025, driven by higher cash earnings.
• Full-year 2025 adjusted EPS guidance midpoint was raised by $0.05 to a range of $16.15 to $16.50.
• Full-year 2025 free cash flow guidance midpoint was raised by $25 million to a range of $1.17 billion to $1.29 billion.
• Strategic acquisitions and partnerships, including Empire City Laboratories, Laboratory Alliance of Central New York, and BioReference Health assets, strengthen market position.
• Advancements in high-growth specialty testing areas like oncology and neurology, with new test introductions and expanded access.
• Investments in digital and AI capabilities, such as Labcorp Test Finder, are enhancing customer experience and operational efficiency.

Negatives

• Full-year 2025 enterprise revenue guidance midpoint was lowered by 40 basis points due to foreign currency translation and acquisition timing.
• The Biopharma Laboratory Services segment experienced lower than anticipated revenue in Early Development, leading to actions to divest or restructure approximately $50 million of annual revenue.

Risks

• The effect of the holding company reorganization on the company's business generally.
• Failure to receive tax-free treatment with respect to the spin-off of the company's Clinical Development and Commercialization Services business, now Fortrea Holdings Inc., for U.S. federal income purposes.
• The impact of spin-off related items.
• Personnel costs and potential difficulties with employee relations and retention.
• The trading price of the company's stock, competitive actions, and other unforeseen changes and general uncertainties in the marketplace.
• Changes in government regulations, including healthcare reform.
• Customer purchasing decisions, including changes in payer regulations or policies.
• Adverse actions of governmental and third-party payers.
• Changes in testing guidelines or recommendations.
• The volume of COVID-19 Testing performed by the company.
• The impact of global geopolitical events.
• The effect of public opinion on the company's reputation.
• Adverse results in material litigation matters.
• Changes in laws and regulations applicable to the company, including healthcare reform, and changes to their interpretation and application and the impact of any such changes.
• Failure to maintain or develop customer relationships.
• The company's ability to develop or acquire new products and adapt to technological changes.
• Failure of the company's information technology, systems, or data security.
• The impact of potential losses under repurchase agreements.
• Adverse weather conditions.
• The number of revenue days in a financial period.
• Inflation.
• Increased competition.
• The effect of exchange rate fluctuations.

Future Outlook

Labcorp updated its full-year 2025 guidance, raising the midpoint for adjusted EPS to a range of $16.15 to $16.50 and for free cash flow to $1.17 billion to $1.29 billion. The enterprise revenue guidance midpoint was slightly lowered to 7.4% to 8.0% growth, primarily due to foreign currency translation and acquisition timing. The company expects to finish the year strong, focusing on delivering value to customers and shareholders, and is taking action to divest or restructure approximately $50 million of annual revenue in its Early Development segment due to lower than anticipated performance.

Management Comments

• Adam Schechter, Chairman and CEO, stated: "Labcorp's third-quarter performance reflects continued momentum in our Diagnostics and Central Laboratory businesses, resulting in strong revenue growth and margin improvement."
• Adam Schechter also noted: "We advanced our strategy by forming new partnerships with health systems and regional laboratories, introducing innovative tests in key specialty areas and leveraging science and technology to improve customer experience and operational efficiency."
• Adam Schechter further commented: "Our performance led to double-digit adjusted EPS growth and strong cash flow in the quarter. We expect to finish the year strong as we remain focused on delivering value to our customers and shareholders."

Industry Context

Labcorp's Q3 2025 performance, marked by strategic acquisitions and advancements in specialty testing (oncology, neurology) and digital capabilities, aligns with broader industry trends. The diagnostics and biopharma laboratory services sectors are experiencing consolidation, a push towards high-growth therapeutic areas, and increasing adoption of digital and AI technologies to enhance efficiency and customer experience. Labcorp's focus on expanding its partnerships with health systems and regional labs reflects a strategic move to capture market share and integrate services, a common theme among leading players in the fragmented healthcare services market.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess results against global benchmarks. Therefore, a direct comparison to specific industry peers' financial metrics or project outcomes is not possible based solely on the provided information.
• However, Labcorp's double-digit adjusted EPS growth and strong free cash flow generation indicate robust operational performance within the laboratory services sector.
• The company's strategic focus on expanding its oncology and genetic testing portfolio, alongside new Alzheimer's tests and digital pathology investments, reflects a proactive approach to innovation and market leadership, consistent with best practices among top-tier diagnostic and biopharma service providers.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased adjusted EPS and free cash flow guidance, and continued capital returns through dividends and share repurchases.
• Employees in the Early Development segment may be impacted by restructuring or divestment actions.
• Customers benefit from expanded service offerings through strategic acquisitions and partnerships, as well as enhanced digital tools and innovative new tests in specialty areas like oncology and neurology.
• Suppliers and partners may see increased business opportunities through Labcorp's growth and strategic initiatives.

Next Steps

• Pay a quarterly cash dividend of $0.72 per share on December 11, 2025, to stockholders of record on November 26, 2025.
• Continue to progress the acquisition of select assets of the outreach business from Community Health Systems across 13 states.
• Take action in response to lower than anticipated revenue in Early Development, including divesting or restructuring approximately $50 million of annual revenue.
• Remain focused on delivering value to customers and shareholders and finishing the year strong.

Key Dates

Recommendation

Labcorp's Q3 2025 results demonstrate robust financial health, with significant year-over-year growth in key metrics like revenue, adjusted EPS, and free cash flow. The upward revision of full-year adjusted EPS and free cash flow guidance signals strong management confidence and positive future outlook. Strategic acquisitions and continued innovation in high-growth specialty testing areas position the company for sustained market leadership and long-term value creation. While there's a slight adjustment to revenue guidance and a planned restructuring in a smaller segment, the overall trajectory and strategic execution warrant a 'buy' recommendation for investors seeking exposure to a leading player in the diagnostics and biopharma laboratory services sector.

Keywords

Labcorp, LH, diagnostics, laboratory services, biopharma, Q3 2025 earnings, financial results, full-year guidance, oncology testing, neurology testing, genetic testing, healthcare, acquisitions, digital pathology